Compare PPL Corporation Common Stock (PPL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPL Corporation Common Stock vs Repligen Corporation Common Stock — how do they compare? PPL Corporation Common Stock trades at $34.99 (market cap $26.06B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: PPL Corporation Common Stock is far larger — about 2.3× Repligen Corporation Common Stock's market cap, and PPL Corporation Common Stock pays a 3.29% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPL Corporation Common Stock for 5 Days and Repligen Corporation Common Stock for 0 Days on average.
| PPL | RGEN | |
|---|---|---|
Market Cap | $26.06B | $11.14B |
Volume | 5,432,693 | 1,259,263 |
Sector | Utilities | Health |
52-Week High | $39.81 | $194.57 |
52-Week Low | $31.97 | $102.87 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $46.05B | $11.02B |
Dividend Yield | 3.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPL Corporation trades at $34.63, up 0.84% with a bullish technical outlook supported by moving averages. The utility company shows solid fundamentals with $9.04B revenue, 13.47% net margin, and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $39.45 price target, representing 14% upside potential from current levels. Recent news highlights PPL's $23B infrastructure investment plan and focus on meeting rising electricity demand through strategic capacity expansion.
PPL presents a compelling investment case with strong analyst support, dividend growth potential, and strategic positioning in the growing utility sector. Key risks include execution challenges from the massive capital expenditure program, regulatory hurdles, and competitive pressures. The stock's current valuation at 20.49 P/E appears reasonable given the company's growth trajectory and defensive characteristics in the utility space.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PPL Corporation Common Stock
PPL Corporation is a regulated utility holding company. Through its subsidiaries, it generates, transmits, distributes, and sells electricity and natural gas in Kentucky, Pennsylvania, and Rhode Island.
Read more on PPL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
